A 12-year of study involving nearly 40,000 U.S. women has
found that regular, low doses of aspirin do not generally
prevent cancer, and vitamin E is ineffective in warding
off heart disease and cancer.
The report did find aspirin might have a protective effect
against lung cancer, but the authors said that needs to
be confirmed with more research, and they pointed out that
there is no way of knowing whether higher doses of aspirin
might have yielded different results.
"However, based on the data currently available, we do
not suggest that doctors recommend low-dose aspirin therapy
for primary prevention of cancer," said Nancy Cook of Brigham
and Women's Hospital in Boston, chief author of the aspirin
study.
While aspirin may not work for cancer, a number of earlier
studies have found it does appear to help prevent heart
disease, a bigger killer of women than cancer.
Tuesday's findings on aspirin and vitamin E were published
in two reports in this week's Journal
of the American Medical Association. Both were based
on data from the Women's Health Study, described as the
largest undertaking of its kind involving the two substances.
There were 39,876 healthy women in the study who were at
least 45 years of age when it began 1992. They were followed
until 2004.
They were divided into four groups. Some got aspirin and
an inert vitamin E placebo; others an aspirin placebo and
real vitamin E; others both both aspirin and vitamin E and
the last group got only placebos for both substances. The
dose levels were 100 milligrams of aspirin and 600 international
units of vitamin E, every other day.
While the aspirin-cancer findings were negative, earlier
data from the same study group released in March found that
the aspirin therapy reduced the risk of stroke by 17 percent,
and in women 65 and older it did reduce the risk of heart
disease, heart attack and stroke.
Eric Jacobs and Michael Thun of the
American Cancer Society, commenting on the aspirin-cancer
results in an editorial in the same journal, said finding
a drug to prevent cancer is inherently difficult.
"It is unrealistic to expect the discovery of an agent
that will produce substantial reductions in overall cancer
rates in the immediate future," they added.
I-Min Lee, also of Brigham and Women's Hospital and chief
author of the vitamin E report, said its findings "do not
support recommending vitamin E supplementation for cardiovascular
disease or cancer prevention among healthy women. At present,
a healthy lifestyle and regular screening for cardiovascular
health and cancer are a woman's best choices for disease
prevention."
The vitamin E study did find a significant reduction in
cardiovascular deaths among all the women taking the vitamin,
and that women 65 and older taking vitamin E had a lower
risk of heart attack, though not stroke.
"These intriguing findings deserve further study," Lee
said. "But they were not part of the primary aim of the
study ... additionally, previous studies of vitamin E in
patients with heart disease have not shown any benefit for
cardiovascular deaths. At present, we cannot recommend vitamin
E for prevention against cardiovascular disease or cancer,"
Elizabeth Nabel, director of the National Heart, Lung and
Blood Institute, which helped fund the study, said "We can
now say that despite their initial promise, vitamin E supplements
do not prevent heart attack and stroke. Instead, women should
focus on well proven means of heart disease prevention."